Abstract
Seventy metastatic breast adenocarcinoma patients, pretreated with standard hormonotherapy or chemotherapy, received continuous UFT at 10 mg/kg/day, orally, for at least two months. There were one complete response (1.5%), 12 partial responses (17%), one minor response and 37 disease stabilizations. The median duration of response was nine months. A greater efficacy was demonstrated in 29 patients with soft tissue disease, with a rate of 38% objective responses. The major toxicity was gastrointestinal, with 45% of patients developing nausea and vomiting and 30%, diarrhea. Bone marrow toxicity was slight. UFT has shown antitumor activity in our group of pretreated patients, especially these with the cutaneous tumoral and/or inflammatory form of the disease.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / secondary
-
Administration, Oral
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Asthenia / chemically induced
-
Bone Neoplasms / secondary
-
Breast Neoplasms / drug therapy*
-
Capsules
-
Chemotherapy, Adjuvant
-
Diarrhea / chemically induced
-
Female
-
Humans
-
Middle Aged
-
Nausea / chemically induced
-
Remission Induction
-
Soft Tissue Neoplasms / secondary
-
Tegafur / administration & dosage
-
Tegafur / adverse effects
-
Uracil / administration & dosage
-
Uracil / adverse effects
-
Vomiting / chemically induced